Lilly’s weight-loss drug Zepbound slashes heart failure risks in study

INDIANAPOLIS – Eli Lilly & Co’s blockbuster Zepbound improved the long-term health of patients with obesity-related heart failure in a study, illuminating the cardiovascular benefits of the weight-loss shot.

The risk of death, hospitalisation and other bad outcomes was 38 per cent lower in patients given Zepbound compared to those who received a placebo, Lilly said on Aug 1. The drug also significantly reduced heart failure symptoms, including shortness of breath, fatigue and an irregular heartbeat.

The company’s shares rose 3.6 per cent before US markets opened.

The two-year trial involving more than 700 patients is part of Lilly’s broader effort to prove that Zepbound, already in high demand for its effects on body weight, can do more than just shrink waistlines. Growing evidence that it improves key components of health may also help the company get insurers to pay for it. 

“That’s what we need to get, not only recognition of the seriousness of the disease, but also reimbursement access,” Mr Jeff Emmick, Lilly’s senior vice-president of product development, said in an interview. 

The company plans to submit results to regulators in the US and abroad later this year, seeking to expand Zepbound’s label. The study involved heart failure patients with a preserved ejection fraction, or HFpEF, a condition closely linked to obesity.

The disease occurs when the heart muscle stiffens, preventing it from filling with enough blood. It affects about 3 million people in the US and as many as 32 million globally, with an annual mortality rate of about 15 per cent, according to a review published last year in the medical journal Jama. 

Novo Nordisk A/S is ahead of Lilly in the race to prove weight-loss drugs can help the heart. Its drug Wegovy was approved for patients with cardiovascular disease in March after a trial showed it cut the risk of heart attacks and strokes by 20 per cent.

That opened the door for Medicare, the government health program for those over 65, to start covering it for more patients. In January, Novo asked regulators to add heart failure to Wegovy’s label after studies showed it improved symptoms.

Lilly has other trials in cardiovascular disease that are still ongoing, and results aren’t expected for at least another year. 

In the meantime, the company is focused on getting Zepbound approved for patients with sleep apnea. It is also studying other conditions like a common liver disease called metabolic dysfunction-associated steatohepatitis, or Mash. Bloomberg